Effective Diagnostic Marker for Serodiagnosis of Toxoplasma gondii Infection: New Developments and Perspectives by Mohamed, Zeehaida & Hajissa, Khalid
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 7
Effective Diagnostic Marker for Serodiagnosis of
Toxoplasma gondii Infection: New Developments and
Perspectives
Zeehaida Mohamed and Khalid Hajissa
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/67907
Abstract
Toxoplasmosis is a prevalent parasitic infection caused by an obligate intracellular para‐
site Toxoplasma gondii. Various methods have been established in the laboratory diagno‐
sis of toxoplasmosis. Among these methods, serological tests are common and provide 
satisfactory results. However, producing reliable reagents and standard antigen remains 
difficult and expensive. Replacing native antigens in all current diagnostic kits with stan‐
dard and reliable reagents are speculated to achieve more sensitive and specific detection 
that can significantly improve the assay performance. This review provides updated data 
on toxoplasmosis serodiagnosis. It focuses on the recent trends of producing reliable and 
standard antigens that have been used in the serological tests of toxoplasmosis, as well as 
the future direction in this field.
Keywords: ELISA, serodiagnosis, multiepitope peptide, recombinant antigen, sensitivity, 
specificity, toxoplasmosis
1. Introduction
Toxoplasmosis is one of the most prevalent parasitic infections caused by an obligate intra‐
cellular parasite Toxoplasma gondii. This parasite can infect almost all warm‐blooded animals 
including humans. The effect of T. gondii on public health and animal production is signif‐
icantly evident worldwide. Therefore, it became one of the well‐studied parasites because 
of its medical and veterinary importance. Although the prevalence rate of toxoplasmosis is 
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approximately one‐third of the world’s human population, T. gondii infection in immuno‐
competent individuals is usually asymptomatic, even though some patients may experience 
fever and other non‐specific clinical signs [1]. In immunocompromised patients, this disease 
may be serious or even fatal; furthermore, primary invasion during pregnancy may endanger 
the life of the fetus as well as the infected mothers [1, 2]. Accurate diagnosis of the acquired 
infection by highly sensitive and specific methods is crucial for proper management of animal 
and human toxoplasmosis and represents the key step in the prevention and treatment of the 
disease [3].
Various methods have been established in the laboratory diagnosis of toxoplasmosis. Among 
these methods, serological tests are common and provide satisfactory results. However, pro‐
ducing reliable reagents remains laborious and expensive. Acquiring a specific and effective 
reagent that can be used in the serodiagnosis is necessary. In the present review, we provide 
updated data on toxoplasmosis serodiagnosis. The review focuses on the recent trends of 
producing reliable and standard antigens that have been used in the serological tests of toxo‐
plasmosis, as well as the future direction in this field.
2. Serodiagnosis
Various direct and indirect detection methods have been established to detect T. gondii infec‐
tious agent or anti‐Toxoplasma antibodies [4]. In particular, different sets of detection methods 
have also been developed and evaluated to achieve accurate diagnosis [5]. There are several 
diagnostic approaches which are applicable to detect the parasitic agents include: histologi‐
cal identification, isolation of the organism in tissue culture [4], and recovery of the parasite 
DNA by the polymerase chain reaction (PCR) [6, 7] or by a combination of these techniques, 
whereas the serodiagnostic tests are mainly designated to detect the different classes of anti‐
bodies or antigens [8].
Despite the various methods of toxoplasmosis investigation, the routine laboratory diagnosis 
in both humans and animals depends mainly on conducting various serological investigations 
to detect specific anti‐Toxoplasma antibodies in serum samples [5, 9]. It remains the primary 
approach to achieve satisfactory results [10]. The production and appearance of each antibody 
isotype are correlated with the immune response after the infection, thus, the determination 
whether the host has got Toxoplasma infection or not can be achieved simply by monitoring 
the immune response especially humoral immunity. The disease symptoms are non‐specific 
and not enough to characterize accurate diagnosis because of clinical signs mimicry between 
toxoplasmosis and several other infections [5, 11]. Many serological tests have been designed 
to measure different types of antibody, which show unique increases and decreases during 
or after infection [12]. All immunoglobulin isotypes have been used successfully in T.  gondii 
 serodiagnosis, including IgG, IgM IgA, and IgE [10]. Specific T. gondii IgM is considered as 
early and sensitive diagnostic marker that correlates with the occurrences of acute toxo‐
plasmosis. Particularly, IgM can be detected in serum only 1 week following the infection. 
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However, it may remain in the serum for several months or years [8]. Thus, the interpretation 
of the serology results sometimes becomes more difficult. Furthermore, the presence of IgM 
antibodies in the maternal circulation even 18 months after invasion influence the accuracy of 
this diagnostic approach because determining whether an antibody is from active or previous 
infection is crucial during gestation [13]. If an antibody is from a previous infection, no con‐
sequences for the fetus normally occur. If the infection occurs during pregnancy, the clinician 
should decide on administering anti‐parasitic treatment to avoid disease complication in the 
unborn child [5, 11]. Recent studies have shown that the use of IgM alone for the establish‐
ment of acute toxoplasmosis is insufficient [8].
Detection of IgG antibodies in patients may aid diagnosis. IgG antibodies can be detected 
within 1–2 weeks following infectionacquisition, and normally peak within 1–2 months, 
and decline at various rates, but usually persist lifelong at residual titers [5, 11]. High levels 
of this antibody indicate previous infection. Therefore, measuring of IgG antibody is a com‐
mon diagnostic marker that helps clinicians to decide whether a patient has chronic infec‐
tion or not. However, this antibody still has difficulty in distinguishing previous infection 
from a recent infection. Consequently, an auxiliary test based on the IgG avidity has been 
established to differentiate acute from chronic infection in an asymptomatic patient [5, 11]. 
In recent years, precise dating and infection have been proven to be obtained by using IgE 
and IgA. However, they produced during the first weeks of infection, and disappear early 
[9]. There are various serological procedures have been established for the detection of anti 
T. gondii antibodies; these include Sabin‐Feldman dye test (SFDT), indirect fluorescent assay 
(IFA), agglutination tests, and enzyme‐linked immunosorbent assays (ELISAs), or a combi‐
nation of these methods are also required for determining recent and previous infections 
[9, 10, 12].
3. Sabin‐Feldman dye test (SFDT)
It was a greatest advancement in the field of toxoplasmosis diagnosis when Sabin and Feldman 
described the dye test as a novel diagnostic test 60 years ago [14]. Though SFDT is the first 
assay developed for the laboratory investigation of T. gondii infection [10], but still considered 
as “gold standard” with high sensitivity and specificity [15]. The principle of the assay is 
based on incubating live tachyzoites with patient serum and complement. Subsequently, if 
the serum contains specific antibodies against T. gondii, it will immediately coat the parasite 
and the tachyzoite will be lysed by the complement system and fail to stain with dye methy‐
lene blue. The number of unstained (dead) and stained (live) tachyzoites will be counted and 
used to establish the end‐point titer [10, 15, 16]. In comparison with other diagnostic tests, 
SFDT has the potential to detect both IgM and IgG. On the other hands, the assay has certain 
limitations. For example, application of live parasite is considered a biohazard; thus, it can be 
only applied in a few laboratories. The antibody titers also do not give strong clues to deter‐
mine whether the infection is acute or chronic [15, 16].
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4. Indirect fluorescent assay (IFA)
IFA is one of the most simple, sensitive, safe, and widely used assays in the usual detec‐
tion of anti‐Toxoplasma antibodies [17]. It has been established as an alternative diagnostic 
method in response to overcome the biohazard of using live tachyzoites in SFDT [10]. 
Diluted serum specimens are incubated with killed Toxoplasma tachyzoites fixed on a glass 
slide to allow specific antigen‐antibody interaction [8]. The interaction will then detected 
by addition of fluorescent‐labeled anti‐human IgG or IgM antibodies, and the result is 
viewed under a fluorescence microscope [18]. Although IFA is relatively inexpensive, 
fluorescence microscope is required, and the individual differences in result reading are 
considered as one of the test limitation. Furthermore, false‐positive results may occur in 
case the sera contain rheumatoid factors or antinuclear antibodies [10]. Nevertheless, high 
levels of T. gondii‐specific IgG in some acute acquired toxoplasmosis patients may interfere 
with the IgM and cause false negative results [19].
5. Agglutination tests
Different agglutination tests, including direct agglutination test (DAT), indirect hemag‐
glutination test (IHAT), and latex agglutination test (LAT), are applied in toxoplasmosis 
serology [9, 12, 20]. Development of DAT assists tremendously in identifying of anti‐T. 
 gondii antibody in humans and animal sera [12]. Fulton achieved this test in 1965; the 
important features of this test are the absence of secondary antibody and no special 
equipment needed. The principle of DAT starting with coating of microtiter plates with 
formalinized Toxoplasma tachyzoites. Diluted patient sera will then added. Accordingly, 
the agglutination will occur if anti‐Toxoplasma antibodies are present in the tested sera. 
However, precipitated tachyzoites will be noticed at the bottom of the wells if the sample 
is negative [21]. The test is very simple and has proved to be very sensitive and inexpen‐
sive, although a large quantity of antigen is required. Despite that DAT is only used for 
detection of IgG antibodies, non‐specific agglutination can be induced by occurrences of 
IgM antibodies [12, 20].
In the IHAT test, red blood cells (RBCs) are sensitized with T. gondii soluble antigen. 
Subsequently, sensitized cells will then incubated with patient sera. Accordingly, the 
RBCs will agglutinate if the sera contain anti‐T. gondii antibodies. Furthermore, IHAT is 
also simple to perform and inexpensive and can be used for both humans and animals [8]. 
In the LAT, tachyzoite particle is fixed to latex beads. When the beads are incubated with 
patient sera containing specific IgG antibody, visible agglutination reaction will occur 
[22]. The disadvantage of this assay is the low sensitivity and specificity, particularly in 
immunocompromised patients; moreover, non‐specific IgM can generate false‐positive 
result [9, 20].
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5.1. Enzyme‐linked immunosorbent assay (ELISA)
ELISA is highly sensitive and specific analytical assay for quantitative detection of antibodies 
or virtually all types of antigenically active molecule. Application of ELISA in the diagno‐
sis of toxoplasmosis has been established since 1976 [23]. Since developed up to now, it has 
been one of the most common biochemical techniques used in research and clinical laborato‐
ries, including detection of anti T. gondii antibodies [8, 24]. In this assay, a microtiter plate is 
coated with antigens, and then diluted patients sera are applied. If the serum contains anti‐ 
Toxoplasma antibodies, it will bind directly to coated antigen, and the presence of Toxoplasma‐
specific antibody will detect by using anti‐human enzyme‐conjugate (secondary antibody). 
Any unbound reagents are removed in the washing steps. Finally, the substrate is added, and 
subsequently, color reaction develops (which is relatively correlated with the quantity of the 
antibody). Interpretation of the ELISA results normally depends on the assessment of color 
change spectrophotometrically [25].
ELISA can easily determine a positive or negative sample by correlating the optical density 
of the serum with the control after a threshold value is established [25]. In general, the advan‐
tages of ELISA test are as follows: it shows high sensitivity which allows quantitative and 
semi‐quantitative antibody measurements, automatically adopted and is inexpensive [26]. 
Furthermore, the assay is simple and easy to carry out and can be used to investigate a large 
number of serum samples in a short period of time [4]. Moreover, it can be used to detect both 
IgG and IgM antibodies [25]. The disadvantage of the ELISA includes standardization of used 
antigens [26]. A photometer is also necessary to assess the results, otherwise, it is difficult to 
distinguish between negative reaction and weak positive reaction by visual examination, and 
this may increase the cost of the test [25]. Generally, detection of anti‐T. gondii IgM antibody 
possesses a high degree of accuracy according to the reports; however, it might sometimes 
give false‐positive result [27]. It is most probably due to the presence of rheumatoid factor in 
serum, and on the other hands, it is common to get false‐negative results due to specific IgG 
competitive inhibition [28].
5.2. Production of reliable and standard antigen for serological diagnosis
Establishing of T. gondii serology is an essential diagnostic tool, which gives satisfactory 
results. However, producing specific and standard antigens is a real challenge. Currently, 
most commercial serological kits use crude Toxoplasma antigens prepared through mouse 
passages or cell culture systems [29, 30]. The soluble native antigen of T. gondii parasite has 
been applied as a diagnostic marker in various seroepidemiological studies [4], a researcher 
used crude native antigen of type I and II, for example [1]. Crude T. gondii tachyzoite antigen 
applied in an indirect ELISA yielded sensitivity and specificity of 95.75 and 85.11%, respec‐
tively [31]. A significant variation between laboratories exists in the process of producing 
native antigen. Furthermore, antigen contamination with non‐parasitic materials is also pos‐
sible because of the lack of standard method for antigen purification [32]. Moreover, the use of 
live pathogens in antigen preparation process needs extra care because of biological hazards 
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generated by the parasite [33]. Therefore, serological tests that use tachyzoite crude antigens 
seem difficult to standardize [32]. To overcome this limitation and improve the serodiagnos‐
tic tests, recombinant antigen may be used as an alternative diagnostic marker, and it could 
replace the native antigens [34].
6. Recombinant antigens
Application of the recombinant antigens in serodiagnostic kits reduces the native antigen pro‐
duction time and significantly reduces the antigen production cost. Furthermore, better test 
standardization is achieved when recombinant antigen is used [35]. Moreover, the particular 
antigenicity of specific antigen can be easily investigated, and with the ability to combine 
more than one antigen to evaluate their diagnostic value, definitely this will facilitate the 
standardization of diagnostic assays [29]. If the synthesis of any selected antigens during the 
parasite life cycle is related to acute or chronic phase of infection, application of this particu‐
lar antigen as discriminating tool leads to significant improvement in Toxoplasma diagnosis 
[35]. The use of recombinant DNA technology to obtain identical antigenic protein helps in 
overcoming the biohazard problem related to native antigens production and is greatly ben‐
eficial to reduce time, cost and labor consumption. Interestingly, one of the most advanta‐
geous of using recombinant antigen in the development of diagnostic tests is that the potential 
to determine precise protein composition, with reduced non‐parasitic material. In addition, 
more than one antigen can be combined in a single test [32].
Recently, several T. gondii antigenic genes have been successfully cloned and expressed using 
various expression systems. Many reports indicate the successful use of recombinant antigen 
in toxoplasmosis serodiagnostic tests [33]. The antigens that have been extensively involved 
in the progress of T. godii diagnosis improvement include the surface antigens (SAGs) [36], 
dense granule antigens (GRAs) [36], microneme antigens (MICs) [37], and rhoptry antigens 
(ROPS) [33]. More details about the application of T. gondii recombinant antigens in the diag‐
nostic studies are illustrated in Table 1. Most previous and current studies approved that 
recombinant protein technology significantly improves the serodiagnosis of T. gondii infec‐
tion. Moreover, the uses of recombinant antigen allow not only the detection of anti‐T. gondii 
antibodies but also differentiation between recently acquired and previous infections, result‐
ing in reduced medical complication risk of the disease in immunocompromised patients, 
especially pregnant women [32]. The potential ability of specific T. gondii recombinant anti‐
gen to identify the clinical phases of the disease was extensively studied, in the attempts to 
discriminate acute from chronic infection. The performance of recombinant antigen seems to 
be sensitive enough and promising in differentiating acute versus chronic infection [35, 38]. 
Although there is no clear definition of either chronic or acute infection, identification of 
recently acquired infection normally relies on the detection of specific IgM in patients serum; 
however, IgM might persist for a long time after infection. Thus, the results may not be precise 
to indicate recent infection, unless the serum is subjected to additional method such as the IgG 
avidity, definitely this will improve the accuracy of identification of the infection occurrence. 
Performance of IgG avidity assay by using T. gondii recombinant antigens may be useful for 
identification of toxoplasmosis phases.
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7. Epitope‐based antigen
The epitope or antigenic determinant is an antigenic part of a protein that possesses the poten‐
tial ability to be recognized by T and B cells receptors or the antibodies binding sites [45]. The 
epitope is classified into two categories based on their primary structure: linear (continuous) 
epitope if the amino acids sequences in the epitope are continuous or conformational (discon‐
tinuous) epitope which composed from discontinuous sections of amino acid [46]. Attempts 
to achieve high sensitive and specific diagnostic assay usually assume that replacing the 
native antigen in all current diagnostic kits by standard and reliable reagents can significantly 
increase the assay performance [30]. In recent years, it has been demonstrated that the use of 
peptide‐based antigen can meet the demand to standardize the serodiagostic test of toxoplas‐
mosis and increase the sensitivity and specificity of these assays. Furthermore, the ability to 
distinguish between previous and recently acquired infection can be also achieved [47].
Theoretically, epitope or multiepitopes show numerous advantages compared with crude 
native antigen because they apply only the antibody‐binding sites of the antigen, which defi‐
nitely increase the accuracy of the test. The applied antigen composition in the serodiagnos‐
tic test will be known precisely, the ability to apply more than one identified epitope, easily 
standardization of the assays, application of only antigen epitope will reduce the biohazard 
problems in using live pathogens [30]. Nowadays, the use of a diagnostic marker that con‐
tains a high density of antibody binding site increases the chances of antibody detection in 
serum samples and provides the potential to acquire inexpensive diagnostic methods with a 
high degree of specificity and sensitivity. Therefore, a great possibility to improve diagnostic 
tests performance exists if multiepitope peptide is applied [48]. Application of multiepit‐
opes antigen in diagnostic tests has been conducted successfully in several studies, employ‐
ing multiepitope peptide in hepatitis C [49], influenza virus [50], leishmaniasis [51], leprosy 
Antigen Diagnostic test Sensitivity % Specificity % Reference
SAG1 ELISA (IgG) 100 100 [39]
Rapid diagnostic test 
(RDT)
100 99.4 [40]
SAG2 ELISA (IgG) 100 89.4 [41]
SAG3 ELISA (IgG) 95.4 91.2 [41]
GRA1 ELISA (IgG) 100 100 [42]
GRA2 Western blot 100 90 [43]
GRA5 Western blot 100 46.8 [38]
GRA7 ELISA (IgG) 93.2 94.0
ROP1 ELISA (IgG) 100 100 [44]
ROP8 Western blot 90 94 [33]
Table 1. Recombinant antigens of T. gondii as serodiagnostic markers.
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[52], Trypanosoma cruzi [53], leptospirosis, and Mycobacterium tuberculosis [54, 55] as well as 
T. gondii infection [30]. In all these studies, multiepitope proteins were proposed to enhance 
the test sensitivity. Identification of specific peptide epitope targeted by the host immuno‐
globulin allows better understanding of the immune response toward the parasite, as well 
as the development of accurate diagnostic tool, for development of diagnostic kit multiepit‐
ope antigen, appears as most promising antigens that can be used in routine toxoplasmosis 
screening [56].
Recently, bioinformatics tools are widely applied for epitope identification in protein analy‐
sis. Consequently, various epitope peptides are used to develop diagnostic antigen and epi‐
tope‐based vaccines [47]. By using software‐based prediction techniques, the SAG1 B cell 
epitope of T. gondii has been analyzed. Consequently, 11 selected peptides were successfully 
synthesized. The potential antigenicity of these peptides was evaluated by ELISA using pig 
sera collected from different periods of post infection. Four of 11 peptides showed high reac‐
tivity and were identified by all sera, whereas the rest of the peptides interacted with selected 
sera only [57]. When the same procedure was applied to T. gondii GRA1, 3 of 11 peptides were 
successfully recognized by all sera. The study suggested that these epitopes can activate the 
host immune system and generate constant immune response because its immunoreactivity 
was not affected when evaluated using sera collected from different time periods following 
the infection [47].
The involvement of GRA1 immunodominant B cell epitope in inducing antibody production 
by the human immune system was previously identified [58], whereas the immunodominant 
epitope on GRA1 was also located and accessed using pig sera. The result indicates high 
immunoreactivity as well as the capability of the peptide to improve the toxoplasmosis sero‐
diagnostic tests [56]. The newly synthesized immunodominant epitopes of T. gondii antigens 
(SAG1, SAG2, SAG3, GRA5, GRA6, and P35) appear to be the most promising diagnostic 
reagents can be applied in routine toxoplasmosis screening The demonstrated multiepitope 
peptides can successfully replace the recombinant antigens for differentiating the recently 
acquired infection from the previous infection; thus, it can serve as an effective tool for human 
serodiagnosis [30].
The advantage of using epitope peptide in serodiagnostic tests can easily increase the assay 
sensitivity by applying different peptides. Alternatively, the use of multiepitope peptide that 
expresses a high density of conserved antigenic determinant can contribute in achieving a 
high degree of sensitivity and specificity [48, 53]. Multiepitope peptide has been evaluated 
to obtain specific and standard antigens for serodiagnosis of T. gondii infection. Findings 
showed promising results for developing more accurate assays with high degree of sensitiv‐
ity and specificity and can differentiate between chronic and acute phases of infection [30, 46]. 
Multiepitope antigen expressed in Escherichia coli system provides the potential to replace 
the currently used crude antigen. This antigen can also contribute in developing accurate 
and inexpensive diagnostic assay with high degree of sensitivity and specificity. Therefore, 
recombinant multiepitope peptide appears as an attractive starting point for future develop‐
ment of T. gondii serodiagnosis and immunization [30, 48].
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8. Concluding remarks
The diagnosis of T. gondii infection is still a huge challenge to the medical knowledge 
and clinical acumen of physicians. Currently, the serological diagnosis plays a vital role 
in the identification of both human and animal toxoplasmosis. However, the insufficient 
accuracy of current diagnostic tests due to the lack of standardization in the production of 
the T. gondii whole‐cell lysate necessitates the exploration of standard diagnostic reagents. 
Nowadays, it is speculated that application of recombinant multiepitope antigens in 
toxoplasmosis serodiagnostic methods would significantly improve the sensitivity and 
specificity of these methods. Accordingly, the increased usage of the bioinformatics and 
recombinant DNA technology will dramatically assist in designing and producing of novel 
epitope‐based antigen, which will be crucial to acquire effective serodiagnostic methods 
for toxoplamosis.
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